SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around token burns tied to watcher milestones, fueling excitement and perceived scarcity. Talk centers on the strong community, the potential for significant upside, and a desire to reach number one on trending lists. The coin is built on the Solana network and the community is anticipating airdrop details.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

Nobody Sausage is a unique online presence that embodies the playful, humorous side of internet culture. Created by Kael Cabral, this character has evolved into a beloved brand that resonates with people through its quirky personality and entertaining content.  Impact and Significance 1. Community building: Nobody Sausage has fostered a sense of community among its fans, who share and engage with its content, creating a collective experience. 2. Entertainment value: The character's quirky personality and humor provide endless entertainment for online audiences, making it a go-to destination for laughs and good times. 3. Cultural relevance: Nobody Sausage has become a symbol of the absurd, joyful aspects of internet culture, reflecting the ever-changing nature of online trends and memes.

Nobody Sausage

Nobody Sausage ($NOBODY.X) is trending as social media users discuss its potential for significant gains, drawing comparisons to other recently successful low market cap cryptocurrencies. Community members are highlighting its low market cap and increasing volume, suggesting it's poised for a substantial surge. The conversation is centered around the potential for quick, high-percentage returns.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

bichi

A memecoin.  Memecoin is exactly what it sounds like—a memecoin called memecoin. In a world dominated by meme-driven hype and community spirit, it only makes sense to have a token that embodies the entire memecoin movement. Launched on PEPE’s birthday, memecoin aims to represent the absurdity, humor, and heart of the memecoin economy. It’s here to bring hope, laughter, and a bit of chaos—while never pretending to be more than it is: just a memecoin. And maybe that’s exactly what we need.

Memecoin

MEMECOIN.X is trending as traders discuss its potential, drawing comparisons to past successes with other low market cap tokens. The community is actively speculating on potential surges, with some mentioning targets and others highlighting its association with the 9gag platform. Conversations mention a possible listing on Binance and the potential for high returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rocket Lab (RKLB) experienced a more than 700% increase in retail user message count on Stocktwits over the last 24 hours as of Wednesday morning, and was the top-trending stock on the platform.Retail sentiment on <a href="https://stocktwits.com/symbol/RKLB">Rocket Lab</a> improved to ‘extremely bullish’ from ‘bullish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:796/107;" src="https://news.stocktwits-cdn.com/RKLB_sentiment_png_2310e5aede.webp" alt="RKLB sentiment.png" width="796" height="107"><figcaption>RKLB sentiment and message volume September 3, 2025, as of 1:10 pm ET | Source: Stocktwits</figcaption></figure>The stock's watchlist count on Stocktwits doubled to 43,281 in a year.Notably, the company's shares declined 10% by midday trading on Wednesday, despite no stock-specific news. The shares appear to have taken a breather following the massive rally seen over the last year. Rocket Lab shares have gained 75% this year and have jumped over 600% over the previous 12 months.Last week, Roth Capital also raised its price target on Rocket Lab to $60 from $50 and maintained a ‘Buy’ rating, according the TheFly. The firm noted that it was impressed by Rocket Lab's progress toward the initial Neutron launch.The Neutron support infrastructure and launch pad infrastructure are all in place for initial launch, Roth Capital said. Rocket Lab opened Launch Complex 3 on August 28, its dedicated test, launch, and landing facility for its reusable rocket, Neutron. The pad is located within the Virginia Spaceport Authority’s (VSA) Mid-Atlantic Regional Spaceport (MARS) at Pad 0D on Wallops Island, Virginia.The company stated that Launch Complex 3 is poised to deliver the largest orbital launch capacity in the Spaceport’s history with Neutron, which is capable of launching 13,000 kg to space for commercial constellations, national security, and interplanetary missions, as well as eventually supporting human spaceflight.In late August, Rocket Lab&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-lifts-off-10-after-70th-electron-launch/chssMD9RdSc">launched</a> its 70th Electron mission as part of its ‘Live, Laugh, Launch’ mission.&nbsp;The ‘Live, Laugh, Launch’ was Electron’s 12th mission of 2025 as Rocket Lab continues to execute an accelerated schedule of Electron launches.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/campbells-ceo-flags-consumer-caution-sees-surge-in-home-cooking/chwcc2mRdoR">Campbell’s CEO Flags Consumer Caution, Sees Surge In Home Cooking And Wellness Demand</a>

Rocket Lab’s 360% surge so far in 2024 has brought CEO Peter Beck’s 10% stake in the company to $970 million. | Source: Rocket Lab USA 

This Aerospace Stock Witnessed A 700% Explosion In Retail Chatter On Stocktwits – More Details Inside

Last week, Roth Capital raised its price target on Rocket Lab to $60 from $50 and noted that it was impressed by the company’s progress toward the initial Neutron launch.

Equity

TG Therapeutics, Inc. (TGTX) on Wednesday stated that its board of directors has authorized a new share repurchase program to acquire up to an additional $100 million of the company’s common stock.The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024. Under the previous program, TG Therapeutics repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. CEO Michael S. Weiss <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> that the company repurchased $78 million of the stock in August alone at “highly attractive prices.”TGTX stock gained nearly 2% in Wednesday’s pre-market.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> on Wednesday that repurchases under the new program may be made on a time-to-time basis through open market purchases, privately negotiated transactions, or other means.Weiss said that the new repurchase program reflects the company’s conviction that “current market prices do not adequately reflect the multibillion-dollar potential of Briumvi or the long-term growth prospects of TG Therapeutics.”Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.In the <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-tumbles-after-disappointing-q2-but-company-reaffirms-confidence-in-multiple-sclerosis-drug/chrXrTDRdcR">second quarter</a>, Briumvi’s net product revenue totaled $138.8 million, representing 91% growth over the same period last year and accounting for over 98% of the company’s total revenue.TGTX stock is down 1% this year but up approximately 31% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tectonic-stock-soars-pre-market-after-tuesday-sell-off/chwTUeNRd8m">Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

 TG Therapeutics Board Authorizes New $100M Share Repurchase Program

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.

Ionis Pharmaceuticals, Inc. (IONS) announced on Tuesday that its medicine, Olezarsen, reduced triglycerides and acute pancreatitis events in late-stage trials evaluating the drug in individuals with severe hypertriglyceridemia.Severe hypertriglyceridemia (sHTG) is defined by severely high triglycerides reaching into the thousands. It is characterized by an increased risk of acute pancreatitis and other morbidities. According to Ionis, approximately three million people are living with sHTG in the U.S., including more than one million who are considered high risk.In two <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute">studies</a>, Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months, as well as a highly statistically significant 85% reduction in acute pancreatitis events, with favorable safety and tolerability profiles. The two trials cumulatively enrolled nearly 1,100 patients who were required to be on standard-of-care lipid-lowering therapy throughout the treatment period.<a href="https://stocktwits.com/symbol/IONS">IONS stock</a> rocketed by 34% by Tuesday afternoon, reaching its February 2021 highs. On Stocktwits, retail sentiment around IONS jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_2_02_09_PM_png_166853294f.webp" alt="IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="59"><figcaption>IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the company’s future.<stembedurl>https://stocktwits.com/Mookins/message/627214651</stembedurl>Sam Tsimikas, senior vice president of global cardiovascular development at Ionis, termed the data “groundbreaking” and noted that the data reinforce the company’s confidence that the medicine has the potential to change how sHTG is treated. According to the firm, current standard of care therapies for sHTG and lifestyle modifications do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients.Ionis plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for approval of Olezarsen in sHTG by the end of the year. The drug is already approved in the U.S. as Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia (FCS).Several analysts hiked their price target on the stock following the news:<ul style="list-style-type:square;"><li>H.C. Wainwright raised its price target to $95 from $70 while keeping a ‘Buy’ rating on the shares. The firm also hiked its forecast for global Olezarsen sales up to $4.2 billion from $3.2 billion.</li><li>Jefferies raised its price target to $96 from $83 and kept a ‘Buy’ rating on the shares. The firm increased its estimate of Olezarsen's peak sales to about $2.5 billion from $1.5 billion due to higher assumed penetration in sHTG.&nbsp;</li><li>Barclays raised its target to $78 from $58, while keeping an ‘Overweight’ rating on the shares.</li><li>Morgan Stanley raised its price target to $71 from $62 and kept an ‘Overweight’ rating on the shares.</li></ul>IONS' stock is up 64% this year and approximately 21% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-expects-sales-bump-for-remainder-of-year-after-new-models-bring-strong-demand/chv6z3WRdFg">Nio Expects Sales Bump For Remainder Of Year After New Models Bring In Strong Demand: Retail Sees Stock Hitting At Least $10 By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies 

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 

Moderna announced on Friday that its updated COVID-19 mRNA vaccine, Spikevax, has received authorization in Canada for those aged six months and older.The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season this fall. The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5951824473215334&amp;symbol=MRNA">added</a> that the pre-filled syringe doses of the vaccine for the market will be made domestically. While the drug substance will be produced at the company’s facility in Laval, Quebec, fill-finish operations will be completed by Novocol Pharma in Cambridge, Ontario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRNA">Moderna</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. Shares of the company traded 5% higher on Friday morning at the time of writing.Health Canada authorized the vaccine based on clinical, non-clinical, and real-world data supporting the vaccine’s safety and efficacy, Moderna said. The updated vaccine targets the SARS-CoV-2 LP.8.1 variant.While those Canadians covered by public programs will receive the vaccine free of charge, the company is also working with private insurers and payers to streamline access and reimbursement within the private sector, it said. The updated COVID-19 vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries. Applications are also under review in other markets.In the second quarter, Moderna reported $114 million in Spikevax sales, including $88 million of U.S. sales and $26 million of international sales. Spikevax sales accounted for 80% of the company’s total revenue in the three months through the end of June.MRNA stock is down by 34% this year and by about 66% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ulta-beauty-gets-upgraded-to-overweight-by-barclays/chsZPwFRd0U">Ulta Beauty Gets Upgraded To ‘Overweight’ By Barclays, But Retail Sentiment Cools Ahead Of Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Gets Clearance To Deliver Updated Spikevax COVID-19 Vaccine In Canada

The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season.

Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure about $700 million of debt.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-refinancing-approximately-700">said</a> it will exchange approximately $700 million in aggregate principal amount of its existing convertible notes due 2027 for roughly $602 million in new 4.875% convertible senior notes due 2030, up to approximately 6.7 million shares of its common stock, and about $123.3 million in cash.Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to investors. A fear of a potential dilution appears to have disappointed investors. SRPT stock was down over 7% at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. The stock is among the top ten trending names on the platform.<figure class="image"><img style="aspect-ratio:569/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_10_26_20_AM_png_8591ecfd20.webp" alt="Screenshot 2025-08-21 at 10.26.20 AM.png" width="569" height="62"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the refinancing.<stembedurl>https://stocktwits.com/scaredmoneymakenomoney/message/626069691</stembedurl>CEO Doug Ingram said that the exchange marks an important progress in the company’s long-term financial strategy. "By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction that significantly enhances our balance sheet flexibility and strengthens our financial position,” Ingram said.Ingram also said that the company believes it is well-positioned to fully fund its pipeline and meet its near-term obligations.Bank of America said that the debt refinancing transaction "makes sense" as it helps mitigate some near-term concerns about the company's ability to meet its obligations. Still, the firm continues to think clarity on uptake of Elevidys from here will be needed to get more comfortable with the long-term outlook.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals. Citi on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/citi-believes-fda-may-closely-watch-sarepta-safeguards-for-gene-therapy-in-non-ambulatory-dmd-patients/chsiUM2RdLP">said</a> that the U.S. Food and Drug Administration may take a “more comprehensive look” at the regimen devised by Sarepta for non-ambulatory patients.Last month, the company said that it had initiated immediate changes to reduce operating expenses, including a 36% workforce reduction and pipeline reprioritization, in a bid to meet its 2027 financial obligations.Following the crisis with the gene therapy, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/analyst-says-sarepta-lost-credibility-by-exiting-arrowhead-at-a-loss/chsRn7vRdON">unwound</a> its equity position in Arrowhead Pharmaceuticals earlier this month, in less than a year of its investment.SRPT stock is down by 84% this year and by about 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-to-invest-2-billion-to-expand-manufacturing-in-north-carolina/chsSyKYRdig">This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Rocket Pharmaceuticals, Inc. (RCKT) on Wednesday said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease.The hold, <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">imposed</a> roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold">said</a>. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.Rocket Pharma stock shot up 25% in Wednesday’s pre-market session following the development. On Stocktwits, retail sentiment around RCKT rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels.&nbsp;Danon disease is a rare, genetic disorder primarily affecting the heart, skeletal muscles, and sometimes the brain. It's characterized by weakening of the heart muscle, muscle weakness, and intellectual disability.Following the death of a patient, Rocket paused further dosing in the mid-stage study, and on May 23, the FDA placed a clinical hold on the trial to allow for further evaluation. The trial can now resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing, followed by additional patients to complete the trial. The low dose has been determined as most likely to confer the safety and efficacy identified in the low-dose early-stage study cohorts, the company said.Rocket also said that it will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting the one administered in the early-stage study pediatric cohort. Further updates about the mid-stage study can be expected following review of data from the next three patients, the company said.RCKT stock is down by 77% this year and by about 85% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rocket Pharma Stock Up 25% Pre-Market Today? 

The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.

PTC Therapeutics, Inc. (PTCT) said on Tuesday that the U.S. Food and Drug Administration refused to approve its application for Vatiquinone for the treatment of children and adults living with Friedreich's ataxia.CEO Matthew B. Klein said that the company is disappointed by the FDA’s decision and plans to meet with the agency to discuss potential steps to address the issues flagged in its complete response letter to the company.In its <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-receives-complete-response-letter-vatiquinone">letter</a>, the FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission. Friedreich's ataxia (FA) is a rare, inherited neurodegenerative disease that primarily affects the nervous system, causing progressive damage to the spinal cord, peripheral nerves, and cerebellum. This leads to impaired muscle coordination, balance problems, and other neurological symptoms.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PTCT">PTCT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_12_18_34_PM_png_b76ebe8504.webp" alt="PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="61"><figcaption>PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock trading in the green despite the news.<stembedurl>https://stocktwits.com/deadlypants/message/625768448</stembedurl>TD Cowen analyst Joseph Thome lowered their price target on PTC Therapeutics to $50 from $56 while keeping a ‘Hold’ rating on the shares following the company’s update. The firm removed Friedreich's ataxia from its model and believes a second successful late-stage study will likely be required for approval.RBC Capital, which has an ‘Outperform’ rating and $63 price target on the stock, meanwhile, believes this was generally expected and already baked into the stock. The firm said that it would still buy the company's shares, according to TheFly.Jefferies analyst Kelly Shi also lowered the firm's price target on PTC Therapeutics to $63 from $64 while keeping a ‘Buy’ rating on the shares. The letter "didn't come in as a surprise to us," said the analyst, who calls the regulatory update "a clearing event" that allows investors to now focus on the launch of a treatment for phenylketonuria.&nbsp;PTCT stock is up by 14% this year and by about 50% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iovance-stock-rises-on-health-canada-approval-for-cancer-immunotherapy/chsgV4qRdW2">Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a PTC Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

The FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission.

Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for Prader-Willi syndrome.The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. It further alleged that the drug may be at risk of being withdrawn from the market, or new prescriptions may plunge.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLNO">Soleno</a> trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_15_at_12_42_29_PM_png_0f8718e0b7.webp" alt="SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits" width="1366" height="124"><figcaption>SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the short seller report, citing inconsistencies with public data.<stembedurl>https://stocktwits.com/aristocks/message/625341208</stembedurl>Another believes the stock is a good buy-the-dip candidate.<stembedurl>https://stocktwits.com/CrispDry/message/625323181</stembedurl>Scorpion Capital said in its report that Soleno is reminiscent of the company Zafgen, which announced two patient deaths in 2015 during a trial with an investigational Prader-Willi syndrome drug, leading to discontinuation of the program. Zafgen subsequently merged with Larimar Therapeutics in 2020.“SLNO is at high risk of fading back into obscurity as a zombie biotech that trades near cash - $9/share - round-tripping back to single-digit or penny stock status, as it was a mere ~2.5 years ago when it hit 90 cents,” Scorpion Capital <a target="_blank" rel="noopener noreferrer nofollow" href="https://scorpionreports.s3.us-east-2.amazonaws.com/SLNO1.pdf">said</a> in its report. The firm further alleged that Soleno has “no meaningful assets, pipeline or scientific program, and its only drug is an inferior tablet version of a half-century-old suspension.”Scorpion Capital also stated that it intends to shortly submit an emergency Citizen Petition asking the FDA to request Soleno to conduct a voluntary recall of VYKAT XR from the market.Soleno <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-gets-fda-approval-for-prader-willi-syndrome-drug/chJ25DRRbE3">received</a> the U.S. Food and Drug Administration’s approval for Vykat XR extended-release tablets for the treatment of hyperphagia in patients four years of age and older with Prader-Willi syndrome in March and subsequently launched it in April. VYKAT XR is the company’s first commercial product.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Scorpion Capital has previously revealed short positions in multiple pharmaceutical and biotechnology companies, including Transmedics Group Inc (TMDX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), and more.SLNO stock is up by 60% this year and by about 42% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cleveland-cliffs-enters-multi-year-steel-deals-with-automakers-report/chsPDjERdfH">Cleveland-Cliffs Enters Multi-Year Steel Deals With Automakers, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet

The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure.

Shares of Inspire Medical Systems, Inc. (INSP) slumped 42% on Tuesday after multiple analysts downgraded the stock on the heels of the company lowering its full-year earnings guidance.The company, which develops solutions for patients with obstructive sleep apnea, cut its full-year revenue guidance on Monday to the range of $900 million to $910 million, down from its previous guidance of $940 to $955 million.Truist downgraded Inspire Medical to ‘Hold’ from ‘Buy’ with a price target of $125, down from $190. The firm was braced for a guidance cut, but it was bigger than expected, and a lower earnings per share outlook reduces the stock valuation floor, the analyst told investors in a post-earnings note.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INSP">INSP</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1250/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_05_at_12_28_15_PM_png_dbcc9ea28f.webp" alt="INSP's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Aug. 5, 2025 | Source: Stocktwits" width="1250" height="126"><figcaption>INSP's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Aug. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the shares are way oversold and will bounce in a few days.<stembedurl>https://stocktwits.com/Sharksbuffs/message/623795533</stembedurl>Inspire now anticipates diluted net income per share guidance for the full year 2025 to be in the range of $0.40 to $0.50, down from its prior guidance of $2.20 to $2.30 per share.Other analysts, too, have downgraded the stock or have cut their price target.<ul style="list-style-type:square;"><li>KeyBanc downgraded the shares to ‘Sector Weight’ from ‘Overweight’ without a price target.&nbsp;</li><li>JPMorgan analyst Robbie Marcus downgraded Inspire Medical to ‘Neutral’ from ‘Overweight’ with a price target of $110, down from $195.&nbsp;</li><li>Piper Sandler kept its ‘Overweight’ rating on the stock while lowering the price target on the shares to $150 from $233. While the firm believed there could be a downward revision, it was disappointed by the magnitude of the cut to both the top and bottom-line guides, it said.</li></ul> INSP stock is down by 59% this year and by 48% over the past 12 months. &nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ardelyx-stock-soars-on-price-target-hikes-after-upbeat-q2-report/chrLvsyRd28">Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Inspire Medical Systems Stock Slumps On Downgrades, Price Target Cuts: Retail Believes Stock Is Way Oversold

Truist said it was braced for a guidance cut, but it was bigger than expected, and a lower earnings per share outlook reduces the stock valuation floor.

CVS Health Corporation (CVS) CFO Brian Newman said during the firm’s earnings call on Thursday that the company raised its full-year profit guidance while maintaining a prudent outlook on medical cost trends.“While medical cost trends remain elevated versus historical periods, in aggregate, they are generally in line to slightly better than our expectations so far this year,” Newman said. “Given this elevated trend environment, we are maintaining a prudent view on medical cost trends through the remainder of the year."The company now expects its full-year medical loss ratio to be approximately 91%, reflecting the actions taken to improve operations in its Aetna health insurance segment.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVS">CVS</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_31_at_10_50_18_AM_png_96951cb153.webp" alt="CVS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on July 31, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>CVS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on July 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic following the earnings beat.<stembedurl>https://stocktwits.com/Reanimated666/message/623187047</stembedurl>Another user noted that the earnings beat from CVS and Humana (HUM) show that things in the health insurance sector aren't “as bad as people are making it out to be.”<stembedurl>https://stocktwits.com/ajew/message/623175366</stembedurl>CVS’ second-quarter <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2025/Q2-2025-Earnings-Release.pdf">earnings</a> surpassed Wall Street expectations. The company now expects full-year adjusted earnings per share of $6.30 to $6.40, up from its previous guidance of $6.00 to $6.20. The firm also expects full-year total revenue to be $391.5 billion, above an analyst estimate of $386.77 billion.CVS operates drugstore chains and a pharmacy benefit management business while also providing insurance through its Aetna segment.For the second quarter, CVS reported total revenues of $98.91 billion, up from $91.23 billion in the corresponding period of 2024, and above an analyst estimate of $94.59 billion, according to data from Fiscal AI.The company’s adjusted earnings per share for the period came in at $1.81, down from $1.83 in Q2 2024, but above an analyst estimate of $1.46.CVS Health's Aetna insurance business reported a medical loss ratio, or the percentage of premiums spent on medical costs, of about 89.9% in the second quarter, up from 89.6% in the corresponding quarter of 2024.CVS stock is up by 41% this year and by about 5% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-announces-10-percent-layoffs-ahead-of-q2-report/choLOX1R56w">Moderna Announces 10% Layoffs Ahead Of Q2 Report: Retail Now Eyes ‘Good Enough’ Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of CVS Health Corporation is displayed on a smartphone screen, with the company's red heart branding visible in the background. (Photo illustration by Cheng Xin/Getty Images)

CVS Health CFO Says Company Maintaining Prudent View On Medical Cost Trends Through Remainder Of Year

The firm now expects full-year adjusted earnings per share of $6.30 to $6.40, up from its previous guidance of $6.00 to $6.20.

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest EAOR News

EAOR iShares ESG Aware 60/40 Balanced Allocation ETF